James B Wetmore1,2, Charles A Herzog3,4, Heng Yan3, Jorge L Reyes5, Eric D Weinhandl3,6, Nicholas S Roetker3. 1. Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota james.wetmore@hcmed.org. 2. Division of Nephrology, Hennepin Healthcare and Department of Medicine, University of Minnesota, Minneapolis, Minnesota. 3. Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, Minnesota. 4. Division of Cardiology, Hennepin Healthcare, and Department of Medicine, University of Minnesota, Minneapolis, Minnesota. 5. Division of Cardiology, University of Minnesota, Minneapolis, Minnesota. 6. Department of Pharmaceutical Care and Health Systems, University of Minnesota, Minneapolis, Minnesota.
Abstract
BACKGROUND AND OBJECTIVES: The association of apixaban compared with warfarin for the treatment of venous thromboembolism in patients receiving maintenance dialysis is not well studied. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective cohort study of Medicare fee-for-service beneficiaries receiving dialysis using United States Renal Data System data from 2013 to 2018. The study included patients who received a new prescription for apixaban or warfarin following a venous thromboembolism diagnosis. The outcomes were recurrent venous thromboembolism, major bleeding, and death. Outcomes were analyzed using Cox proportional hazards regression for intention-to-treat and censored-at-drug-switch-or-discontinuation analyses. Models incorporated inverse probability of treatment and censoring weights to minimize confounding and informative censoring. RESULTS: In 12,206 individuals, apixaban, compared with warfarin, was associated with lower risks of both recurrent venous thromboembolism (hazard ratio [HR], 0.58; 95% confidence interval [95% CI], 0.43 to 0.77) and major bleeding (HR, 0.78; 95% CI, 0.62 to 0.98) in the intention-to-treat analysis over 6 months of follow-up. However, there was no difference between apixaban and warfarin in terms of risk of all-cause death (HR, 1.04; 95% CI, 0.94 to 1.16). Corresponding hazard ratios for the 6-month censored-at-drug-switch-or-discontinuation analysis and for corresponding analyses limited to a shorter (3-month) follow-up were all highly similar to the primary analysis. CONCLUSIONS: In a large group of US patients on dialysis with recent venous thromboembolism, we observed that apixaban was associated with lower risk of recurrent venous thromboembolism and of major bleeding than warfarin. There was no observed difference in mortality.
BACKGROUND AND OBJECTIVES: The association of apixaban compared with warfarin for the treatment of venous thromboembolism in patients receiving maintenance dialysis is not well studied. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective cohort study of Medicare fee-for-service beneficiaries receiving dialysis using United States Renal Data System data from 2013 to 2018. The study included patients who received a new prescription for apixaban or warfarin following a venous thromboembolism diagnosis. The outcomes were recurrent venous thromboembolism, major bleeding, and death. Outcomes were analyzed using Cox proportional hazards regression for intention-to-treat and censored-at-drug-switch-or-discontinuation analyses. Models incorporated inverse probability of treatment and censoring weights to minimize confounding and informative censoring. RESULTS: In 12,206 individuals, apixaban, compared with warfarin, was associated with lower risks of both recurrent venous thromboembolism (hazard ratio [HR], 0.58; 95% confidence interval [95% CI], 0.43 to 0.77) and major bleeding (HR, 0.78; 95% CI, 0.62 to 0.98) in the intention-to-treat analysis over 6 months of follow-up. However, there was no difference between apixaban and warfarin in terms of risk of all-cause death (HR, 1.04; 95% CI, 0.94 to 1.16). Corresponding hazard ratios for the 6-month censored-at-drug-switch-or-discontinuation analysis and for corresponding analyses limited to a shorter (3-month) follow-up were all highly similar to the primary analysis. CONCLUSIONS: In a large group of US patients on dialysis with recent venous thromboembolism, we observed that apixaban was associated with lower risk of recurrent venous thromboembolism and of major bleeding than warfarin. There was no observed difference in mortality.
Authors: Jennifer D Guo; Patrick Hlavacek; Lisa Rosenblatt; Allison Keshishian; Cristina Russ; Jack Mardekian; Mauricio Ferri; Tayla Poretta; Huseyin Yuce; Robert McBane Journal: Thromb Res Date: 2020-12-08 Impact factor: 3.944
Authors: Bakhtawar K Mahmoodi; Ron T Gansevoort; Inger Anne Næss; Pamela L Lutsey; Sigrid K Brækkan; Nic J G M Veeger; Ellen E Brodin; Karina Meijer; Yingying Sang; Kunihiro Matsushita; Stein I Hallan; Jens Hammerstrøm; Suzanne C Cannegieter; Brad C Astor; Josef Coresh; Aaron R Folsom; John-Bjarne Hansen; Mary Cushman Journal: Circulation Date: 2012-09-13 Impact factor: 29.690
Authors: Jennifer D Guo; Jigar Rajpura; Patrick Hlavacek; Allison Keshishian; Janvi Sah; Rachel Delinger; Qiao Mu; Jack Mardekian; Cristina Russ; Gary J Okano; Lisa Rosenblatt Journal: J Manag Care Spec Pharm Date: 2020-05-26
Authors: Clive Kearon; Elie A Akl; Joseph Ornelas; Allen Blaivas; David Jimenez; Henri Bounameaux; Menno Huisman; Christopher S King; Timothy A Morris; Namita Sood; Scott M Stevens; Janine R E Vintch; Philip Wells; Scott C Woller; Lisa Moores Journal: Chest Date: 2016-01-07 Impact factor: 9.410
Authors: Salim S Virani; Alvaro Alonso; Hugo J Aparicio; Emelia J Benjamin; Marcio S Bittencourt; Clifton W Callaway; April P Carson; Alanna M Chamberlain; Susan Cheng; Francesca N Delling; Mitchell S V Elkind; Kelly R Evenson; Jane F Ferguson; Deepak K Gupta; Sadiya S Khan; Brett M Kissela; Kristen L Knutson; Chong D Lee; Tené T Lewis; Junxiu Liu; Matthew Shane Loop; Pamela L Lutsey; Jun Ma; Jason Mackey; Seth S Martin; David B Matchar; Michael E Mussolino; Sankar D Navaneethan; Amanda Marma Perak; Gregory A Roth; Zainab Samad; Gary M Satou; Emily B Schroeder; Svati H Shah; Christina M Shay; Andrew Stokes; Lisa B VanWagner; Nae-Yuh Wang; Connie W Tsao Journal: Circulation Date: 2021-01-27 Impact factor: 29.690
Authors: Pamela L Lutsey; Rob F Walker; Richard F MacLehose; Alvaro Alonso; Terrence J Adam; Neil A Zakai Journal: Res Pract Thromb Haemost Date: 2019-06-09